New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health

NEW YORK, July 2, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.

--
Curis, Inc. Analyst Notes
On June 23, 2014, Curis, Inc. (Curis) announced that Roche, which has a collaboration agreement with the Company to develop and commercialize Erivedge®, filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a multicenter, Phase 2 clinical study of Erivedge® (vismodegib) in patients with idiopathic pulmonary fibrosis (IPF). The Company stated that Erivedge® is built to selectively target the Hedgehog signaling pathway, implicated in the development of certain types of cancer. Ali Fattaey, Ph.D., President and CEO of Curis said, "We are pleased with this important decision by Roche to expand the development of Erivedge outside of oncology for the first time, especially in IPF where Hedgehog pathway activation is associated with the disease. The IND filing is currently under review by the FDA and we look forward to providing additional details on the study as they become available." The full analyst notes on Curis are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/CRIS/report.pdf

--
Enzo Biochem, Inc. Analyst Notes
On June 23, 2014, Enzo Biochem, Inc. (Enzo Biochem) announced that along with its subsidiary, Enzo Life Sciences, Inc., it has entered into a settlement agreement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc., regarding an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No. 03-CV-3817. The Company stated that pursuant to the agreement, PerkinElmer, Inc. has agreed to pay $7 million in escrow in settlement. The full analyst notes on Enzo Biochem are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/ENZ/report.pdf

--
Applied Genetic Technologies Corp Analyst Notes
On June 24, 2014, Applied Genetic Technologies Corp (AGTC) and SAFC Commercial (SAFC), the Sigma-Aldrich Corporation business unit manufacturing specialty chemicals and biologics for commercial life science applications, announced that they have signed an agreement to have SAFC provide gene therapy manufacturing services to companies that develop gene-based therapies. AGTC informed that under the terms of the agreement, both companies will jointly market AGTC's proprietary HAVE manufacturing method with SAFC's cGMP manufacturing capabilities. The Company stated that it will assist clients to engineer AAV-based vectors and the associated helper virus for HAVE-based manufacturing activities, and SAFC will manufacture AAV vectors with the HAVE system to support initial research or support clinical trial development and eventual commercial production in accordance with cGMP production. AGTC added that this partnership will also give clients access to bio-manufacturing testing services from SAFC's biologics and early-development services business, BioReliance. The full analyst notes on AGTC are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/AGTC/report.pdf

--
Halozyme Therapeutics, Inc. Analyst Notes
On June 25, 2014, Halozyme Therapeutics, Inc. (Halozyme) announced that the commercial launch in Europe of MabThera® SC for the treatment of follicular lymphoma and diffuse large B-cell lymphoma, has triggered a $5 million milestone payment to the Company during Q2 2014 under the License and Collaboration Agreement between Halozyme and Roche. According to the Company, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented Enhanze™ (recombinant human hyaluronidase) technology to be launched in Europe, after Herceptin® SC. The full analyst notes on Halozyme are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/HALO/report.pdf

--
Magellan Health Inc Analyst Notes
On June 26, 2014, Magellan Health Inc (Magellan Health) announced the appointment of Stewart Lavelle as Chief Sales and Marketing Officer, reporting to Magellan Health's Chairman and CEO, Barry M. Smith, effective July 14, 2014. Magellan Health stated that in this role, Lavelle will work closely with the Company's strategic business unit CEOs to ensure growth and set the strategic road map for the Company's sales and marketing efforts. The full analyst notes on Magellan Health are available to download free of charge at:

http://www.analystsreview.com/Jul-02-2014/MGLN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review